• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

Recent Advances in the Study of 4-(4-n-Butylpiperidin-1-yl)butanenitrile (CAS: 244291-78-9): A Comprehensive Research Brief

4-(4-n-Butylpiperidin-1-yl)butanenitrile (CAS: 244291-78-9) is a chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This nitrile-containing piperidine derivative has shown potential in various therapeutic applications, particularly in the modulation of neurological and metabolic pathways. Recent studies have focused on its synthesis, pharmacological properties, and potential as a lead compound for drug development. This research brief aims to provide an overview of the latest findings related to this compound, highlighting its chemical characteristics, biological activities, and future research directions.

The synthesis of 4-(4-n-Butylpiperidin-1-yl)butanenitrile has been optimized in recent years to improve yield and purity. Advanced techniques such as microwave-assisted synthesis and catalytic hydrogenation have been employed to enhance the efficiency of the production process. The compound's structural features, including the piperidine ring and the nitrile functional group, contribute to its unique physicochemical properties, such as solubility and stability, which are critical for its pharmacological applications. Researchers have also explored its stereochemistry, revealing insights into its interaction with biological targets.

Pharmacological studies have demonstrated that 4-(4-n-Butylpiperidin-1-yl)butanenitrile exhibits notable activity in modulating neurotransmitter systems. Specifically, it has been investigated for its potential as a dopamine receptor modulator, with implications for treating neurological disorders such as Parkinson's disease and schizophrenia. In vitro and in vivo studies have shown that the compound can cross the blood-brain barrier, a crucial factor for its efficacy in central nervous system (CNS) targets. Additionally, preliminary data suggest its role in metabolic regulation, particularly in lipid metabolism, opening avenues for research in obesity and diabetes.

Recent preclinical trials have further elucidated the safety and toxicity profile of 4-(4-n-Butylpiperidin-1-yl)butanenitrile. Acute and subchronic toxicity studies in animal models have indicated a favorable safety margin, with no significant adverse effects observed at therapeutic doses. However, long-term toxicity and pharmacokinetic studies are still underway to fully assess its potential for clinical use. The compound's metabolism has also been studied, revealing its biotransformation pathways and the formation of active metabolites that may contribute to its pharmacological effects.

In conclusion, 4-(4-n-Butylpiperidin-1-yl)butanenitrile (CAS: 244291-78-9) represents a promising candidate for further drug development. Its versatile pharmacological profile, combined with its manageable toxicity, makes it a valuable subject of ongoing research. Future studies should focus on elucidating its mechanism of action, optimizing its formulation, and conducting clinical trials to validate its therapeutic potential. This research brief underscores the importance of continued investigation into this compound, which may lead to breakthroughs in treating neurological and metabolic disorders.

• 164926-88-9(2-(1-methyl-4-piperidyl)acetonitrile)
• 20691-92-3(1-methylpiperidine-4-carbonitrile)
• 202002-66-2(2-(Piperidin-4-yl)acetonitrile)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)